$AMRS Company News Insider filings one way to track

New Post Public Reply Private Reply Replies (0) Message Board

Jan 9, 2014 at 2:58 PM

$AMRS Company News

Insider filings one way to track tricky micro-cap biotechs 11:14 a.m. Oct. 24, 2012 - blogs.marketwatch.com
Amyris soars 18% on Total biofuels deal 9:19 a.m. July 31, 2012 - Val Brickates Kennedy
U.S. benchmarks revisit less-charted territory 10:22 a.m. July 12, 2012 - Michael Ashbaugh
Tuesday’s biggest gaining and declining stocks 3:49 p.m. June 5, 2012 - MarketWatch
TransCanada wins $3.8 billion pipeline job 3:22 p.m. June 5, 2012 - Steve Gelsi
Amyris soars 26% on jet fuel update 11:16 a.m. June 5, 2012 - Val Brickates Kennedy
Why Warren Buffett hates gold 5:49 a.m. May 8, 2012 - The Trading Deck
Tuesday’s biggest gaining and declining stocks 5:37 p.m. Feb. 28, 2012 - Kate Gibson
Monday’s biggest gaining, declining stocks 5:21 p.m. Feb. 27, 2012 - Sue Chang
Renewable fuel scales up, hits bumps 3:39 a.m. Feb. 17, 2012 - Steve Gelsi
Friday’s biggest gaining and declining stocks 3:21 p.m. Feb. 10, 2012 - MarketWatch
Amyris down 27% on equity financing plans 11:47 a.m. Feb. 10, 2012 - Steve Gelsi
What matters in Amazon's report 8:56 a.m. Oct. 26, 2011 - The Trading Deck
VC John Doerr fired up on energy research 5:58 p.m. Sept. 28, 2011 - Steve Gelsi
First Solar shares fall 5% 10:08 a.m. Sept. 16, 2011 - Steve Gelsi
TMO Renewables may seek U.K. listing: investor 2:06 p.m. June 8, 2011 - Steve Gelsi
Another clean-tech IPO imminent, Khosla says 1:58 p.m. March 3, 2011 - John Letzing
IPOs attracting buyers at bargain prices 1:28 p.m. Sept. 30, 2010 - Steve Gelsi
Amyris CEO Speaks on Energy IPO 2:57 p.m. Sept. 28, 2010 - Anthony Lazarus

Amyris: Can This Industrial Biotechnology Pioneer Still Thrive? 7:01 p.m. Jan. 5, 2014 - Seeking Alpha
Morning Market Losers 9:14 a.m. Jan. 2, 2014 - benzinga.com
Amyris, Inc. (AMRS) Soars: Stock Up 16.0% - Tale of the Tape 8:51 a.m. Dec. 30, 2013 - Zacks.com
Amyris Meets Funding Milestones, Announces $28M Private Placement from New and Existing Investors 7:42 a.m. Dec. 24, 2013 - benzinga.com
Amyris (AMRS) Looks Good: Stock Adds 5.6% in Session - Tale of the Tape 9:04 a.m. Dec. 23, 2013 - Zacks.com
Amyris +2.7% on commercialization progress 8:24 a.m. Dec. 18, 2013 - Seeking Alpha
Commodities Today: Oil And Alternative Fuels In The News 12:58 p.m. Dec. 5, 2013 - Seeking Alpha
Amyris, Total form JV to produce and commercialize renewable fuels 10:28 a.m. Dec. 5, 2013 - Seeking Alpha
Amyris (AMRS) Looks Good: Stock Adds 6.5% in Session - Tale of the Tape 9:15 a.m. Dec. 3, 2013 - Zacks.com
Losers in a Less-Corny EPA Fuel Rule 10:51 a.m. Nov. 20, 2013 - Barrons.com
BioAmber 3Q: Sarnia Still On Track And Supports Valuation 12:12 p.m. Nov. 19, 2013 - Seeking Alpha
There Goes The Biofuels Mandate 12:14 p.m. Nov. 17, 2013 - Seeking Alpha
Amyris: The Q3 Balance Sheet Is Stronger Than It Looks 7:40 a.m. Nov. 11, 2013 - Seeking Alpha
The Dangers Of Relying On Next-Gen Biofuel Cost Estimates 8:04 a.m. Nov. 8, 2013 - Seeking Alpha
10-Q: AMYRIS, INC. 6:15 a.m. Nov. 5, 2013 - Edgar Online - (EDG = 10Q, 10K)
Amyris Management Discusses Q3 2013 Results - Earnings Call Transcript 7:30 p.m. Oct. 31, 2013 - Seeking Alpha
This 1 Crucial Trait May Determine The Winner Of The Biofuel Wars 1:30 p.m. Sept. 26, 2013 - streetauthority.com
BioAmber Remains A Risky Investment As It Pursues Commercialization 10:56 a.m. Sept. 17, 2013 - Seeking Alpha
Green Plains Renewable Energy's New Dividend And Its Sustainability 10:40 p.m. Aug. 23, 2013 - Seeking Alpha
Amyris Has Potential But Is Still Reliant On Outside Cash 12:55 p.m. Aug. 15, 2013 - Seeking Alpha

Amyris Meets Funding Milestones and Announces $28 Million Private Placement With Participation From New and Existing Investors 8:40 a.m. Dec. 24, 2013 - GlobeNewswire
Amyris Continues Successful Commercialization 4:01 p.m. Dec. 17, 2013 - GlobeNewswire
Amyris and TOTAL Form Fuels Joint Venture 9:57 a.m. Dec. 5, 2013 - GlobeNewswire
Amyris Announces Transition of Chief Financial Officer 8:00 a.m. Nov. 15, 2013 - GlobeNewswire
Amyris Reports Third Quarter 2013 Financial Results 3:00 p.m. Oct. 31, 2013 - GlobeNewswire
Amyris to Enter Partnership to Supply Renewable Jet Fuel to GOL Airlines 3:02 p.m. Oct. 23, 2013 - GlobeNewswire
Amyris to Announce Third Quarter Financial Results on Thursday, October 31, 2013 3:01 p.m. Oct. 17, 2013 - GlobeNewswire
Amyris Meets Major Milestone at Its Farnesene Production Facility 7:00 a.m. Oct. 11, 2013 - GlobeNewswire
Amyris to Present at the Advanced Biofuels Leadership Conference 3:10 p.m. Oct. 7, 2013 - GlobeNewswire
Amyris to Present at the Credit Suisse Small & Mid Cap Conference 7:30 a.m. Sept. 13, 2013 - GlobeNewswire
Amyris Reports Second Quarter 2013 Financial Results 3:00 p.m. Aug. 8, 2013 - GlobeNewswire
Amyris Signs Agreement for Up to $60 Million in Funding From Temasek 6:45 a.m. Aug. 8, 2013 - GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on AMRS, KIOR, REGI and SZYM 7:41 a.m. Aug. 7, 2013 - ACCESSWIRE
Amyris to Announce Second Quarter Financial Results on Thursday, August 8, 2013 7:00 a.m. July 23, 2013 - GlobeNewswire
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Amyris, Inc. to Contact the Firm 8:30 p.m. July 12, 2013 - GlobeNewswire
Law Office of Brodsky & Smith, LLC Notifies Amyris Investors of Upcoming July 15, 2013 Deadline in Putative Class Action Lawsuit - AMRS 2:28 p.m. July 10, 2013 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors With Losses on Their Investment in Amyris, Inc. of Class Action Lawsuit and the Deadline of July 15, 2013 to Seek a Lead Plaintiff Position 11:40 a.m. July 9, 2013 - BusinessWire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors With Losses on Their Investment in Amyris, Inc. of Class Action Lawsuit and the Deadline of July 15, 2013 to Seek a Lead Plaintiff Position 12:42 p.m. July 2, 2013 - PR Newswire
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Amyris, Inc. To Contact The Firm 9:09 a.m. June 29, 2013 - PR Newswire
Amyris and Total Announce Successful Demonstration Flight With Renewable Jet Fuel During Paris Air Show 6:00 a.m. June 20, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...